Tenax Therapeutics' Working on Phase 2 Trial

TL;DR

10x Therapeutics is a biotech company focused on cardiovascular and cardio-pulmonary diseases, particularly pulmonary hypertension. They are currently conducting a phase 2 clinical trial for a promising drug called levosimendan.

Transcript

so I'm here at the biotech showcase today in San Francisco I'm talking with 10x therapeutics Michael Jepsen the CFO and Anthony just do tow know the company's CEO so could we get a little rundown on the company see what's going on recently sure so we are a company that is focused on cardiovascular and cardio pulmonary diseases areas that have high ... Read More

Key Insights

• 🥰 Levosimendan, developed by Orion, has already been approved in over 60 countries for acute decompensated heart failure.
• ❓ The current phase 2 clinical trial for pulmonary hypertension is expected to provide proof of concept for the drug's effectiveness.
• ☠️ The trial is relatively short, enrolling 36 patients over six weeks, and involves top-rated institutions as potential investigators.
• 💪 10x Therapeutics has a strong financial position, with enough funds to complete phase 2 and receive feedback from the FDA.
• 😒 The drug's extensive clinical data and global use provide a significant advantage for regulatory submissions.
• 😷 Ongoing research continues to showcase additional applications for levosimendan in various medical areas.
• 👀 Investors should look forward to updates on enrollment and milestones in the clinical trial.

Questions & Answers

Q: What is 10x Therapeutics focused on treating?

10x Therapeutics is focused on cardiovascular and cardio-pulmonary diseases, particularly pulmonary hypertension, which currently lacks approved therapies.

Q: What is the unique mechanism of action of levosimendan?

Levosimendan is a calcium sensitizer with potassium channel activity, making it a promising drug for cardiovascular conditions. It has been used in over a million and a half patients with acute decompensated heart failure.

Q: What is the timeline for the current clinical trial?

The phase 2 trial will enroll 36 patients throughout 2019, and the company expects to have top-line data by the end of the year. If successful, they will then design a phase 3 program for approval.

Q: How does the recent financing impact the company's plans?

With $10 million raised, the company has sufficient funds to complete phase 2 and analyze the data. Additional financing may come from warrants attached to the recent financing, potentially reaching up to $20 million.

Summary & Key Takeaways

• 10x Therapeutics is enrolling patients in a phase 2 clinical trial for pulmonary hypertension, a condition with an unmet medical need.

• Their drug, levosimendan, is a novel first-in-class calcium sensitizer that has already been approved in over 60 countries for acute decompensated heart failure.

• The company expects to have top-line data from the trial by the end of the year, which will determine their next steps towards commercialization.